Abstract
The aim of this retrospective study was to assess the value of a serum tumour marker panel in selecting from among the patients with equivocal chest X-ray (CXR) or liver echography (LE) those with thoracic or liver metastases respectively. Between January 1984 and December 1999, 467 (341 non-relapsed and 126 metastatic) breast cancer patients were followed-up postoperatively. Among the 126 metastatic patients 36 showed thoracic (19 patients) or liver (17 patients) metastases, alone or in conjunction with other organs as the first evidence of distant spread. We focused on this series of 377 patients including 341 non-relapsed plus 36 with liver or thoracic metastases. The patients were followed-up after mastectomy with serial determinations of a panel of CEA-TPA-CA15.3 tumour markers, bone scintigraphy, CXR and LE. Up to December 1999, equivocal CXR occurred in 23 (6.1%) patients of whom 11 (47.8%) developed thoracic metastases; 14 (3.7%) patients showed an equivocal LE of whom 5 developed liver metastases. In the 37 patients with equivocal CXR or equivocal LE prolonged clinical and imaging follow-up over 41 ± 36 months (mean ± SD, range 3–163) was used to ascertain the presence or absence of thoracic or liver metastases. In the 23 patients with equivocal CXR the negative and positive predictive values of the tumour marker panel to predict thoracic metastases were 92% and 100% respectively. In the 14 patients with equivocal LE the negative and positive predictive values of the tumour marker panel for prediction of liver metastases were 90% and 100% respectively. This study shows that in breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value for selecting those patients at high risk of developing clinically evident pulmonary or liver metastases from amongst those subjects with equivocal CXR or equivocal LE. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
ASCO Special Article (1996 Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843–2877
Ciatto S and Herd-Smith A (1983 The role of chest x-ray in the follow-up of primary breast cancer. Tumori 69: 151–154
Fargnoli R, Carrieri G and Nizzi Grifi D (1999 Torace: patologia polmonare e pleurica. DalPozzo GTomografia computerizzata e TC spirale, Utet: Torino 519–592
Fogelman I (1991 Bone scanning. Maisey MN, Britton KE, Gilday DL (eds) Clinical Nuclear Medicine, Chapman and Hall Medical: London pp 131–157
Horton J (1984 Follow-up of breast cancer patients. Cancer 53: 790–797
Kruskal JB and Kane RA (1992 Correlative imaging of malignant liver tumors. Semin Ultrasound CT MR 13: 336–354
Logager VB, Vestergaard A, Herrstedt J, Thomsen HS, Zedeler K and Dombernowsky P (1990 The limited value of routine chest X-ray in the follow-up of stage II breast cancer. Eur J Cancer 26: 553–555
Loomer L, Brockschmidt JK, Muss HB and Saylor G (1991 Post-operative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature. Cancer 67: 55–60
Muss HB, McNamara MJ and Connelly RA (1988 Follow-up after stage II breast cancer: A comparative study of relapsed versus non relapsed patients. Am J Clin Oncol 11: 451–455
Neville AM, Patel S, Capp M, Laurence DJ, Cooper EH, Turberville C and Coombes RC (1978 The monitoring role of plasma CEA alone and in association with other tumour markers in colorectal and mammary carcinoma. Cancer 42: 1448–1451
Nicolini A and Carpi A (2000 postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumor Biol 21: 235–248
Nicolini A, Carpi A, Di Marco G, Giuliani L, Giordani R and Palla S (1989 A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer 63: 2037–2046
Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L (1991a Evaluation of serum CA15.3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154–158
Nicolini A, Carpi A and Tibaldi C (1991b The postoperative management of breast cancer patient: new concepts. Carpi A, Sagripanti A, Mittermayer CH (eds), pp 187–203, Sympomed Medical Publisher: Munchen Progress in Clinical Oncology,
Nicolini A, Anselmi L, Michelassi C and Carpi A (1997 Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 76: 1106–1111
Nicolini A, Ferrari P, Sagripanti A and Carpi A (1999 The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 79: 1443–1447
Pandya KJ, McFadden ET, Kalish LA, Tormey DC, Taylor SG 4th and Falkson J (1985 A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 55: 202–205
Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V (1994 Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271: 1593–1597
Schapira DV and Urban N (1991 A minimalist policy for breast cancer surveillance. JAMA 265: 380–382
Schlegel G, Luthgens M, Eklund G and Bjorklund B (1981 Correlation between activity in breast cancer and CEA, TPA and eighteen common laboratory procedures and the improvement by the combined use of CEA and TPA. Tumor Diagn 2: 6–11
The GIVIO Investigators (1994 Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 271: 1587–1592
Winchester DP, Sener SF, Khandeskar JD, Oviedo MA, Cunningham MP, Caprini JA, Burkett FE and Scanlon EF (1979 Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 43: 956–960
Author information
Authors and Affiliations
Additional information
Department of General Surgery, University of Pisa, Pisa, Italy
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nicolini, A., Carpi, A., Ferrari, P. et al. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer 83, 1412–1417 (2000). https://doi.org/10.1054/bjoc.2000.1477
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1477
Keywords
This article is cited by
-
Evaluation of contrast Sonazoid-enhanced ultrasonography for the detection of hepatic metastases in breast cancer
Breast Cancer (2016)
-
CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients
BMC Cancer (2014)
-
Surveillance après traitement de cancer du sein (hors mutation)
Oncologie (2009)
-
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
BMC Cancer (2006)